肝臓の血管新生素の損失は,心不全で発射部位が保存されたときの腹動機能障害を軽減する
Zetao Heng1,2,3,4,5, Min Hong1,2,3,4,5, Zhaocai Zhang6
1Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|September 1, 2025
まとめ
肝臓血管新生素 (AGT) ターゲティングは,保存されたエジェクション分数 (HFpEF) による心不全における腹動機能障害を改善します. この研究で明らかになったのは
科学分野:
- 心血管研究
- 分子医学
- 腎臓生理学
背景:
- 発射分子が保存された心不全 (HFpEF) はダイアストリック機能不全を伴う複雑な症候群であり,治療法も少ない.
- レニン- 血管新生系 (RAS) は心不全に関与しているが,血管新生素 (AGT) のHFpEFにおける特定の役割は不明である.
研究 の 目的:
- 保存されたエジェクション分数 (HFpEF) の心不全の病原性における血管新生素 (AGT) の因果的役割を調査する.
- HFpEFにおける肝臓のAGTを標的とした潜在的な治療戦略を探求する.
主な方法:
- HFpEF (高脂肪食 + L-NAME) の2つのヒットマウスモデルを使用しました.
- 肝細胞特異のAGT消去と全身アンジオテンシンII阻害 (ロサルタン) の効果を評価した.
- LRP2,GATA2/Pim3シグナル伝達,およびマイクロ血管新生を含む分子メカニズムを調査した.
主要な成果:
- HFpEFマウスでは肝臓と血のAGTの上昇が観察された.
- 肝細胞特異のAGT消去は,雄性および雌性HFpEFマウスにおいて,ダイアストリック機能を改善した.
- 系統的なロサルタンは心臓のダイアストリック機能を改善しませんでした.
- 肝臓のAGTは,LRP2媒介によるHFpEFを誘導し,GATA2/ Pim3信号を抑制し,血管新生を抑制し,腹動機能不全を悪化させることが判明した.
- 肝臓のAGT阻害剤である18β- glycyrrhetinic acidは,HFpEFマウスの腹動機能を有意に改善しました.
結論:
- 肝臓のAGTは,HFpEFの病原性における重要な因果因子である.
- 肝臓のAGTを標的とした治療は,HFpEFに対する有望な治療戦略です.
関連する概念動画
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:22Heart Failure Drugs: Diuretics
483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
01:29Heart Failure II: Pathophysiology
37
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
37
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:17Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
871
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
871